You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
重藥控股(000950.SZ)控股子公司獲得藥品註冊證書
格隆匯 05-05 17:57

格隆匯5月5日丨重藥控股(000950.SZ)發佈公吿,公司下屬控股子公司重慶醫藥(集團)股份有限公司(以下簡稱“重藥股份”)近日收到國家藥品監督管理局核准簽發的《藥品註冊證書》,藥物名稱:枸櫞酸託法替布片。

枸櫞酸託法替布片是由輝瑞公司研發的一種Janus激酶(JAK)抑制劑,用於治療炎性相關的多種免疫性疾病,2012年首先在美國上市,2017年進入中國,商品名為尚傑/XELJANZ。本品批准的適應症有類風濕關節炎、銀屑病關節炎、強直性脊柱炎。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account